Related Experiment Video
Updated: Jun 6, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines
H Zhang1, S Guttikonda, L Roberts
1Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA.
Abstract:
Non-small-cell lung cancer (NSCLC) is the most deadly type of cancer in the United States and worldwide. Although new therapy is available, the survival rate of NSCLC patients remains low. One hallmark of cancer cells is defects in the apoptotic cell death program. In this study, we investigate the role of B-cell lymphoma 2 (Bcl-2) family members Bcl-2, Bcl-x(L) and Mcl-1, known to regulate cell survival and death, in a panel of fourteen NSCLC cell lines. NSCLC cell lines express high levels of Mcl-1 and Bcl-x(L), but not Bcl-2. Silencing the expression of Mcl-1 with small interfering RNA (siRNA) oligonucleotides potently killed a subgroup of NSCLC cell lines. In contrast, Bcl-x(L) siRNA had no effect in these lines unless Mcl-1 siRNA was also introduced. Interestingly, high MCL1 to BCL-xl messenger RNA determines whether the cells depend on Mcl-1 for survival. We further investigated the role of Mcl-1 in NSCLC cells using a Mcl-1-dependent cell line, H23. The expression of a complementary DNA containing only the coding region of MCL1 rescued H23 cells from the toxicity of a 3' untranslated region (UTR) targeting Mcl-1 siRNA but not a siRNA targeting the coding region of MCL1. Furthermore, we show that Mcl-1 sequesters the BH3-only protein Noxa and Bim and the apoptotic effector Bak. Not surprisingly, Noxa, Bim, or Bak knockdown partially rescued H23 cells from toxicity mediated by Mcl-1 siRNA to different degrees. Collectively, our results indicate that targeting Mcl-1 may improve therapy for a subset of NSCLC patients.
Insights
Targeting Mcl-1, a key survival protein, shows promise for treating non-small-cell lung cancer (NSCLC). Silencing Mcl-1 effectively killed some NSCLC cells, suggesting a new therapeutic strategy for this deadly disease.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- Non-small-cell lung cancer (NSCLC) has a low survival rate despite available therapies.
- Cancer cells often exhibit defects in programmed cell death (apoptosis).
- Bcl-2 family proteins (Bcl-2, Bcl-x(L), Mcl-1) regulate apoptosis and cell survival.
Purpose of the Study:
- To investigate the role of Bcl-2 family members (Bcl-2, Bcl-x(L), Mcl-1) in NSCLC cell lines.
- To determine if targeting Mcl-1 can be a therapeutic strategy for NSCLC.
Main Methods:
- Analysis of Bcl-2 family member expression in fourteen NSCLC cell lines.
- Silencing Mcl-1 or Bcl-x(L) expression using small interfering RNA (siRNA).
- Investigating Mcl-1's interaction with BH3-only proteins (Noxa, Bim) and Bak in NSCLC cells.
Main Results:
- NSCLC cell lines predominantly express high levels of Mcl-1 and Bcl-x(L), not Bcl-2.
- Mcl-1 silencing potently killed a subset of NSCLC cell lines, while Bcl-x(L) silencing had limited effect.
- The ratio of MCL1 to BCL-XL mRNA determined Mcl-1 dependency.
- Mcl-1 was shown to sequester Noxa, Bim, and Bak, proteins involved in apoptosis.
Conclusions:
- Mcl-1 plays a critical role in the survival of a subset of NSCLC cells.
- Targeting Mcl-1, possibly by modulating its interaction with apoptotic proteins, may offer a novel therapeutic approach for NSCLC patients.
